Contact us 24/7


Crestor May Increase Risk of Heart Attack and Stroke

Crestor is a cholesterol-reducing drug manufactured by AstraZeneca. Crestor works to lower cholesterol levels by inhibiting HMG-CoA reductase, which plays a key role in the production of cholesterol in the liver. It is in a group of cholesterol drugs known as “statins.”

Since its approval in August of 2003, the FDA has issued several warnings concerning the safety of statin drugs like Crestor, specifically about the risk of adverse events like rhabdomyolysis, heart attack, and stroke.


  • March 2004– Consumer advocacy group Public Citizen files a petition asking the FDA to remove Crestor from the market due to reported cases of life-threatening rhabdomyolysis and kidney failure/kidney damage.
  • January 2005- AstraZeneca reports that a patient died while taking Crestor. Data from consequent studies indicate that certain people (Asian-Americans, those taking the immune suppressant cyclosporine, and patients with severe kidney problems) are at greater risk for muscle injury due to Crestor.
  • March 2005- The FDA issues a Public Health Advisory about label changes to Crestor which outline the risks of serious muscle toxicity (myopathy/rhabdomyolysis), especially at the highest approved dose of 40 mg.
  • October 2011- AdverseEvents, a group that analyzes the FDA’s adverse event data, claim that Crestor users are at a higher risk of muscle injury than those who use other statins.
  • January 2012- A study published in the Archives of Internal Medicine links Crestor with Type-2 Diabetes in women.


  • Diabetes
  • Liver Damage
  • Kidney Damage
  • Chronic Bleeding
  • Heart Attack or Heart Failure
  • Rhabdomyolysis (deterioration of the muscles)


If you’ve been injured, we can help. Contact us